Lung Ultrasound Can Influence the Clinical Treatment of Pregnant Women With COVID‐19. (1st June 2020)

• Record Type: Journal Article
• Authors: Yassa, Murat; Birol, Pinar; Mutlu, Ali Memis; Tekin, Arzu Bilge; Sandal, Kemal; Tug, Niyazi
• Is Part Of: Journal of ultrasound in medicine. Volume 40:Number 1(2021)
• Page Start: 191
• Page End: 203
• Publication Date: 2020-06-01
• Subjects: COVID‐19 -- lung ultrasound -- pneumonia -- pregnancy -- severe acute respiratory syndrome novel coronavirus 2; Ultrasonics in medicine -- Periodicals; Ultrasonics; Ultrasonography; Ultrasonics in medicine; Electronic journals; Periodicals; Periodicals; 616.07543
• DOI: 10.1002/jum.15367
• Languages: English
• ISSNs: 0278-4297

Abstract

Abstract : Lung ultrasound (LUS) is an effective tool to detect and monitor patients infected with 2019 coronavirus disease (COVID‐19). The use of LUS on pregnant women is an emerging trend, considering its effectiveness during the outbreak. Eight pregnant women with a diagnosis of COVID‐19 confirmed by nasal/throat real‐time reverse transcription polymerase chain reaction testing who underwent point‐of‐care LUS examinations after routine obstetric ultrasound are described. A routinely performed LUS examination revealed serious lung involvement in 7 cases: 2 were initially asymptomatic; 3 have chest computed tomography; 1 had initial negative real‐time reverse transcription polymerase chain reaction results; and 1 had initial negative computed tomographic findings. Treatment for COVID‐19 was either commenced or changed in 87.5% of the patients (n = 7 of 8) on LUS findings. Among patients with abnormal LUS findings, treatment was commenced in 5 patients (71.5%) and changed in 2 patients (28.5%). One normal and 7 abnormal LUS cases indicate the impact of routine LUS on the clinical outcome and treatment of pregnant women.